Imanixil

Imanixil (HOE-402 free base) is an orally active LDL receptor (LDLR) inducer. Imanixil can reduce cholesterol levels by inhibiting VLDL-lipid production. Imanixil can delay atherosclerosis profession. Imanixil can be used for the research of cardiovascular disease, such as atherosclerosis[1].

Product Specifications

CAS Number

[75689-93-9]

Product Name Alternative

HOE-402 (free base)

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

LDLR

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

COVID-19-immunoregulation

Field of Research

Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/imanixil.html

Purity

99.29

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C(C1=CN=C(N2CC(C)(C)NC2=O)N=C1N)NC3=CC=CC(C(F)(F)F)=C3

Molecular Formula

C17H17F3N6O2

Molecular Weight

394.35

Precautions

H302, H315, H319, H335

References & Citations

[1]Draijer R, et al. HOE 402 lowers serum cholesterol levels by reducing VLDL-lipid production, and not by induction of the LDL receptor, and reduces atherosclerosis in wild-type and LDL receptor-deficient mice. Biochem Pharmacol. 2002 May 1;63 (9) :1755-61.